Onderneming Synthetic Biologics Inc Nyse
Aandelen
US87164U1025
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 62 | 01-06-15 | |
Michael Kaleko
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-12 |
- | - | ||
T. J. Swope
SEC | Corporate Secretary | - | - |
Manel Cascalló
PRN | Corporate Officer/Principal | - | 23-03-22 |
Vince Wacher
PRN | Corporate Officer/Principal | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jeff Wolf
BRD | Director/Board Member | 60 | 01-01-06 |
John Monahan
BRD | Director/Board Member | 77 | 11-11-20 |
Jeffrey Kraws
CHM | Chairman | 59 | 01-01-06 |
Chief Executive Officer | 62 | 01-06-15 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 17 868 282 | 16 816 750 ( 94,12 %) | 720 233 ( 4,031 %) | 94,12 % |
Bedrijfsgegevens
Theriva Biologics, Inc.
9605 Medical Center Drive Suite 270
20850, Rockville
+301 417 4364
http://www.therivabio.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |